ADC Therapeutics SA ADCT R2KR3KPHARMA
Company Overview
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound' and ADCT-602 that is in a Phase 1/2 IIT in refractory B-cell acute lymphoblastic leukemia. Further, the company's pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, NaPi2b, and ASCT2. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
Why Investors Should Care
Generates a return on equity of 76.8%, reflecting efficient use of shareholder capital.
Recent Developments
- Dec 2025 Revenue of $81.36M (+14.9% YoY); net profit $-142.62M.
- Trailing 12 Months Year-on-year growth — revenue -9.5%.
- 5-Year Trend Long-term compounding — revenue CAGR -27.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -27.09% |
| 1 Year: | -9.50% |
Stock Price Performance
| 1 Year: | -55.99% |
| 6 Months: | -66.91% |
| 3 Months: | +32.04% |
| 1 Month: | +20.35% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)65.49 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 76.8%.
CONS
- Revenue declined at -27.1% CAGR over 5 years.
- Trading 72.1% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ADCT ADC Therapeutics SA R2KR3KPHARMA | 1.36 | -1.40 | $172.98M | 0.00% | -42.38% | 76.75% | -27.09% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 18.95M | 19.20M | 14.27M | 17.85M | 17.03M | - | - | 23.03M | 18.84M | 16.43M | 23.06M | 20.85M |
| Cost of Revenue | - | - | - | - | - | - | - | 2.06M | 836.00K | 1.20M | 1.70M | 3.62M |
| Gross Profit | - | - | - | - | - | - | - | 20.97M | 18.00M | 15.22M | 21.36M | 17.24M |
| Operating Expenses | - | - | - | - | - | - | - | 49.16M | 48.58M | 45.55M | 39.48M | 42.48M |
| Operating Income | -50.21M | -39.65M | -36.15M | -33.61M | -29.04M | - | - | -28.18M | -30.57M | -30.33M | -18.12M | -25.25M |
| EBITDA | - | - | - | - | - | - | - | -25.75M | -41.21M | -27.45M | 6.31M | -20.50M |
| Interest Expense | - | - | - | - | - | - | - | 12.23M | 13.00M | 13.39M | 13.01M | 12.35M |
| Pretax Income | - | - | - | - | - | - | - | -38.44M | -55.39M | -40.97M | -6.81M | -32.97M |
| Tax Provision | - | - | - | - | - | - | - | 165.00K | 1.25M | 0 | -404.00K | 0 |
| Net Income | -59.37M | -48.92M | -46.73M | -46.61M | -36.54M | - | - | -38.60M | -56.65M | -40.97M | -6.41M | -32.97M |
| Diluted EPS | -0.73 | -0.60 | -0.57 | -0.56 | -0.38 | - | - | -0.36 | -0.50 | -0.30 | -0.04 | -0.21 |
| R&D Expense | 38.38M | 31.34M | 27.08M | 25.73M | 24.30M | 32.50M | - | 28.93M | 30.09M | 26.80M | - | 19.88M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 209.91M | 69.56M | 70.84M | 81.36M |
| Cost of Revenue | - | 3.30M | 2.53M | 5.95M | 5.80M |
| Gross Profit | - | 206.61M | 67.03M | 64.89M | 75.56M |
| Operating Expenses | - | 329.59M | 232.08M | 194.48M | 182.77M |
| Operating Income | - | -122.99M | -165.05M | -129.59M | -107.21M |
| EBITDA | - | -107.70M | -145.83M | -102.65M | -88.10M |
| Interest Expense | - | 36.73M | 46.33M | 50.21M | 51.63M |
| Pretax Income | - | -146.82M | -195.42M | -156.14M | -141.61M |
| Tax Provision | - | 227.00K | 39.11M | 166.00K | 1.01M |
| Net Income | - | -157.13M | -240.05M | -157.85M | -142.62M |
| Diluted EPS | - | -1.99 | -2.94 | -1.62 | -1.12 |
| R&D Expense | - | 186.46M | 127.13M | 109.63M | 104.00M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 490.86M | 354.78M | 321.98M | 323.15M |
| Current Assets | - | 434.98M | 336.29M | 291.25M | 306.33M |
| Cash & Equivalents | - | 326.44M | 278.60M | 250.87M | 261.34M |
| Inventory | - | 12.07M | 16.18M | 2.25M | 4.18M |
| Receivables | - | 72.97M | 25.18M | 20.32M | 29.12M |
| Total Liabilities | - | 411.41M | 503.03M | 524.62M | 508.98M |
| Current Liabilities | - | 81.94M | 67.67M | 80.47M | 70.16M |
| Long Term Debt | - | 109.71M | 112.73M | 113.63M | 112.45M |
| Total Debt | - | 117.38M | 124.38M | 123.00M | 117.02M |
| Total Equity | - | 79.45M | -148.25M | -202.64M | -185.83M |
| Shares Outstanding | - | 89.04M | 89.04M | 101.61M | 128.31M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -138.31M | -118.69M | -123.83M | -141.17M |
| Investing Cash Flow | - | -687.00K | -3.22M | -867.00K | 395.00K |
| Financing Cash Flow | - | -897.00K | 73.88M | 97.05M | 150.94M |
| Capital Expenditure | - | -687.00K | -3.22M | -867.00K | -264.00K |
| Free Cash Flow | - | -139.00M | -121.90M | -124.70M | -141.44M |
| Net Change in Cash | - | -139.90M | -48.03M | -27.65M | 10.17M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 98.4% | 96.4% | 91.6% | 92.9% |
| Operating Margin % | - | -58.6% | -237.3% | -182.9% | -131.8% |
| Net Margin % | - | -74.9% | -345.1% | -222.8% | -175.3% |
| ROE % | - | -197.8% | 161.9% | 77.9% | 76.7% |
| ROCE % | - | -30.1% | -57.5% | -53.7% | -42.4% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Nantahala Capital Management, LLC | 9.65% | 12.33M | $14.05M |
| 2 | Redmile Group, LLC | 9.03% | 11.53M | $13.14M |
| 3 | TCG Crossover Management, LLC | 8.92% | 11.39M | $12.98M |
| 4 | Prosight Management, Lp | 6.13% | 7.82M | $8.92M |
| 5 | Blackrock Inc. | 5.50% | 7.02M | $8.00M |
| 6 | Point72 Asset Management, L.P. | 2.86% | 3.65M | $4.16M |
| 7 | Morgan Stanley | 2.39% | 3.05M | $3.48M |
| 8 | Millennium Management Llc | 2.27% | 2.90M | $3.31M |
| 9 | Citadel Advisors Llc | 1.61% | 2.05M | $2.34M |
| 10 | Goldman Sachs Group Inc | 1.50% | 1.91M | $2.18M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ADCT
ADC Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the 2026 Cantor Global Healthcare Conference in New York, NY, on Friday, September 11, 2026, at 9:10 a.m. ET…
ADC Therapeutics (ADCT) Q2 2026 Earnings Call Transcript
FDA raised safety concerns about ZYNLONTA combination therapy in LOTIS-5 trial.
ADC Therapeutics (ADCT) Stock Fair Value Falls After LOTIS 5 Reshapes Zynlonta Outlook
The central fair value estimate for ADC Therapeutics has been cut from US$5.00 to about US$3.33, which marks a sizeable reset in modeled upside for the stock. Analysts are linking these lower targets to mixed LOTIS-5 outcomes, a more cautio…
ADC Therapeutics SA (ADCT) (Q2 2026) Earnings Call Highlights: Navigating Regulatory Hurdles ...
ADC Therapeutics reports stable Zynlonta sales and cost savings, but faces FDA concerns over LOTUS-5 that cloud the path to full approval.
ADC Therapeutics Q2 Earnings Call Highlights
ADC Therapeutics (NYSE:ADCT) reported second-quarter 2026 net product revenue of $18.6 million for ZYNLONTA, up from $18.1 million in the prior-year period, while executives said the treatment’s commercial performance remained broadly consi…
ADC Therapeutics SA (ADCT) Reports Q2 Loss, Lags Revenue Estimates
ADC Therapeutics (ADCT) delivered earnings and revenue surprises of +42.11% and -4.48%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
ADCT — Frequently Asked Questions
What is the current share price of ADC Therapeutics SA (ADCT)?
As of 2026-09-07 16:24 PDT, ADC Therapeutics SA (ADCT) trades at $1.36 on NYSE. Its 52-week range is $0.96 to $4.88.
What is the market capitalisation of ADCT?
ADC Therapeutics SA (ADCT) has a market capitalisation of $172.98M on NYSE.
What is the P/E ratio of ADCT?
ADCT trades at a trailing price-to-earnings (P/E) ratio of -1.40. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is -0.66.
What is the return on equity (ROE) of ADCT?
ADCT has a return on equity (ROE) of 76.75%. Its return on capital employed (ROCE) is -42.38%.
Is ADCT a good stock to buy?
This page provides a data-driven analysis of ADC Therapeutics SA (ADCT), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.